Patient-led Follow-up from Home After Surgery for Colorectal Carcinoma

NCT ID: NCT06613581

Last Updated: 2024-09-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-18

Study Completion Date

2031-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary goal of the patient-led follow-up from home, is the improvement of quality of life and the reduction of stress in patients, while obtaining a more complete picture of their health status.

A series of assessments are performed in the home setting:

* Blood withdrawal for CEA determination
* Quality of life questionnaires to assess both mental and physical symptoms
* Vital parameters using a Smart Sensor

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Objective: To further develop and evaluate a personalised patient-centred surveillance programme including a feedback platform for patients after curative treatment for CRC in terms of health-related quality of life (HRQoL) and significantly decrease the number of in-hospital appointments, by relocating the follow-up care to the home-setting. The goal is for this surveillance program to be non-inferior to standard of care follow-up at 36 months, in terms of quality of life. The quality of life in patients will be assessed with the EQ 5D-5L questionnaire and compared to median EQ-5D-5L scores for patients receiving standard of care follow-up. In current literature, the median HRQoL VAS score for patients after surgery for CRC is 62.05 points (1).

The second goal of the program is to relocate part of the in-hospital follow-up care to the home-setting. In standard of care follow-up, at 36 months patients would have had 10 in-hospital appointments. The effect of the PROMISE study on the number of in-hospital appointments, will be assessed at 36 months postoperatively.

The PROMISE study is a multi-centre prospective regional implementation study of a personalised patient-centred surveillance program including a feedback platform for patients after curative treatment for CRC.

All patients who underwent surgery with curative intent for non-metastatic CRC with scheduled postoperative surveillance are potentially eligible.

Follow-up in this study is performed according to the acting Dutch national guidelines. Current guidelines advocate CEA level measurements to be performed every 3-6 months for first 2 years after surgery and every 6-12 months for years 3 to 5. Medical imaging (thoracic and abdominal CT) should be performed 1 year postoperatively. Changes to the Dutch national guidelines during the course of the study will be implemented accordingly into the follow-up.

Within this study surveillance will for the greater part be performed at home:

* Serum CEA level monitoring is performed using the automatic capillary blood withdrawal device (TAP-II) - every 6 months during the first two years and every 12 months thereafter
* Vital parameters will be measured with a LifeSignals Multi-parameter Remote Monitoring System - every 3 months during the first two years and every 6 months thereafter
* QoL is measured with the use of questionnaires - every 3 months during the first two years and every 6 months thereafter
* One scheduled in hospital evaluation with medical imaging (according to national guidelines) performed 1 year after surgical treatment

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Carcinoma (CRC)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

All patients included in the study will be followed-up according to the home-based follow-up protocol. The PROMISE study is an implementation study, to further develop and improve home-based follow-up.
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Implementation of home-based follow-up

All patients within the PROMISE study are included in the 'experimental' arm. The study is set up as an implementation study, meaning that the home-based method of follow-up is applied to all patients in the study.

Group Type EXPERIMENTAL

Home-based follow-up

Intervention Type OTHER

Follow-up after surgery for colorectal carcinoma, performed from home, within the bounds of the Dutch National guidelines

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Home-based follow-up

Follow-up after surgery for colorectal carcinoma, performed from home, within the bounds of the Dutch National guidelines

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 21 years
* Histologically confirmed colorectal adenocarcinoma without distant metastasis and treated with curative intent surgical resection less than 6 months ago
* Scheduled or currently undergoing postoperative surveillance according to national guidelines
* Written informed consent by the patient
* Access to a smartphone

Exclusion Criteria

* Patients with a severely complicated postoperative course, needing in hospital follow- up longer than 6 months postoperatively
* Patients enrolled in other studies that require strict adherence to any specific follow-up practice with regular imaging - yearly or more frequent - of the abdomen and/or thorax
* Patients with comorbidity or other malignancy that requires imaging of the abdomen and/or thorax every year or more frequent
* Patients with active implantable devices - e.g. pacemaker or implantable defibrillator
* Inability to complete the questionnaires due to illiteracy and/or insufficient proficiency of the Dutch language
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Lifesignals Inc.

UNKNOWN

Sponsor Role collaborator

YourBio Health

UNKNOWN

Sponsor Role collaborator

TU Delft

UNKNOWN

Sponsor Role collaborator

Amphia Hospital

OTHER

Sponsor Role collaborator

Leiden University Medical Center (LUMC)

UNKNOWN

Sponsor Role collaborator

Franciscus Gasthuis & Vlietland (location Rotterdam)

UNKNOWN

Sponsor Role collaborator

Erasmus Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

D.J. (Dirk) Grünhagen

Surgical oncologist, MD, PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dirk J. Grunhagen, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Erasmus Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Amphia Hospital

Breda, North Brabant, Netherlands

Site Status NOT_YET_RECRUITING

IJsselland Hospital

Capelle aan den IJssel, South Holland, Netherlands

Site Status NOT_YET_RECRUITING

Leiden University Medical Center

Leiden, South Holland, Netherlands

Site Status NOT_YET_RECRUITING

Erasmus Medical Center

Rotterdam, South Holland, Netherlands

Site Status RECRUITING

Franciscus Gasthuis and Vlietland

Rotterdam, South Holland, Netherlands

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Elise M.H.E. van Driel, MD

Role: CONTACT

+310107042125

Lissa Wullaert, MD

Role: CONTACT

0031 0107042125

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Paul Gobardhan, MD, PhD

Role: primary

Pascal Doornebosch, MD, PhD

Role: primary

Koen C.M.J. Peeters, MD, PhD

Role: primary

Dirk J. Grunhagen, MD, PhD

Role: primary

Maria Verseveld, MD, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

84788

Identifier Type: OTHER

Identifier Source: secondary_id

NL84788.078.23

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The AIDPRO-CRC Trial
NCT06645015 RECRUITING NA